Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

49.36 +0.34 (+0.69%)
Streaming Delayed Price Updated: 10:18 AM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
47 48 Next >
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
Via Benzinga
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Via Benzinga
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?
These titans of big pharma just enrolled patients into phase 3 clinical trials for this promising blood thinner. 
Via The Motley Fool
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?
One of these big pharma stocks is considerably more attractive as a pure-play value investment. 
Via The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? 
Via News Direct
Exposures Product Safety
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Where Bristol-Myers Squibb Stands With Analysts
Via Benzinga
This Big Pharma Stock Is a Clear Buy
This drugmaker is one of the most well-known in the world. 
Via The Motley Fool
A Bearish Sign Appears On Bristol-Myers Squibb's Chart
Via Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Successful Autologous Cell-Based Therapies 
Via Benzinga
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Via Benzinga
Wall Street Is Bullish on GE HealthCare as It Invests in AI
The stand-alone company that spun off from GE in January is off to a good start. 
Via The Motley Fool
4 Top Value Stock ETFs for Long-Term Wealth Building
It could be value's time to shine for the first time in years. 
Via The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
Both companies have outperformed the market over the past year. 
Via The Motley Fool
2 Top Biotech Stocks to Buy Right Now
These two companies each pay market-beating dividends to shareholders. 
Via The Motley Fool
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
It's still unclear whether CMS will include those drugs in its negotiation list. 
Via Investor's Business Daily
Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows
These are blue chip stocks you can hold in your portfolio for many years. 
Via The Motley Fool
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Via Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
7 Dividend Stocks to Buy During a Market Downturn
If you are still in search of total returns in this down market, then looking for dividend stocks to buy is a smart strategy for your portfolio. 
Via InvestorPlace
Why Nektar Therapeutics Stock Is Plunging Today
Via Benzinga
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
These pharmaceutical stocks probably won't stay so attractively valued for too much longer. 
Via The Motley Fool
I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.
We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right? 
Via InvestorPlace
Bristol Myers' Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years
Via Benzinga
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer
Via Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.